Researchers recently conducted a multicenter observational cohort study to examine the condition severity and the clinical outcomes of patients with different Clostridium difficile strains. The ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Researchers at Rhode Island Hospital (Providence) have developed a new test for Clostridium difficile able to distinguish between strains of varying virulence, according to research published in the ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

The bacterium Clostridium difficile — otherwise known as C. diff — spreads within intensive care units more than three times as much as previously thought, according to a study published on April 4 in ...

A notorious bacterium is spreading through hospitals more easily than thought Researchers found Clostridium difficile spreading 3.6 times more than suspected in ICUs More than half the time, C. diff ...

Scientists in Pennsylvania have developed an experimental mRNA-based vaccine for C. diff bacteria, which often cause recurring, miserable bouts of diarrhea. Reading time 3 minutes We might soon have a ...

Two new studies have revealed more about a bacterial pathogen that can infect the gut, Clostridium difficile. There are many strains of C. diff, some of which crank out toxic chemicals that damage gut ...

SALT LAKE CITY — Hospital rooms might look spotless, but a recent study from the University of Utah reveals something alarming hiding in plain sight. The bacteria Clostridioides difficile, commonly ...

INDIANAPOLIS--(BUSINESS WIRE)--Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced the presentation of ...

Scientists have discovered how the hospital superbug C.diff rapidly evolves resistance to the frontline drug used for treatment in the UK. Scientists have discovered how the hospital superbug C.diff ...